The median defined daily dose (DDD) [48] was calculated separately for antipsychotics, mood stabilizers including lithium, and antidepressants
From topical research: Most commonly reported observation: mild transient redness at application site (attributed to vascular activity from VEGF stimulation) No systemic adverse events reported in human topical studies at standard concentrations No evidence of carcinogenicity or mutagenicity in available in vitro models From injectable research (preclinical): At supratherapeutic doses in animal models, mild injection site reactions have been noted No organ toxicity observed in standard preclinical safety panels No immunogenicity concerns identified (consistent with its endogenous structure) Copper considerations: GHK-Cu delivers a small amount of bioavailable copper
No equivalence should be assumed
Timpel P, Oswald S, Schwarz PEH, Harst L (2020) Mapping the evidence on the effectiveness of telemedicine interventions in diabetes, dyslipidemia, and hypertension: an umbrella review of systematic reviews and meta-analyses
"GLP-1 Weight Loss Drug Demonstration Begins July 2026"
But it is nowhere near the miracle the viral videos suggest and it is not remotely comparable to GLP-1 medications or bariatric surgery